Paper · 42470517
Genetic spectrum and treatment implications of maturity-onset diabetes of the young in the eastern Black Sea region of Türkiye: a combined adult and pediatric cohort of 296 patients with identification of rare and novel variants.
Doğan Ç and 5 others. Mol Biol Rep, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Genetic spectrum and treatment implications of maturity-onset diabetes of the young in the eastern Black Sea region of Türkiye: a combined adult and pediatric cohort of 296 patients with identification of rare and novel variants. Papers, record 42470517. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42470517
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Genetic spectrum and treatment implications of maturity-onset diabetes of the young in the eastern Black Sea region of Türkiye: a combined adult and pediatric cohort of 296 patients with identification of rare and novel variants.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Humans | |
| Male | |
| Female | |
| High-Throughput Nucleotide Sequencing | |
| Retrospective Studies | |
| Turkey | |
| Adult | |
| Child | |
| Adolescent | |
| Young Adult | |
| Mutation | |
| Genetic Testing | |
| Child, Preschool | |
| Cohort Studies | |
| Middle Aged | |
| Sulfonylurea Receptors |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40,486,195 | Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/40486195 | PubMed |
| 2 | 14,575,972 | Genetic cause of hyperglycaemia and response to treatment in diabetes. | Lancet | 2003 | https://conductscience.org/library/papers/14575972 | PubMed |
| 3 | 30,793,219 | Genetic Dissection and Clinical Features of MODY6 (NEUROD1-MODY). | Curr Diab Rep | 2019 | https://conductscience.org/library/papers/30793219 | PubMed |
| 4 | 41,772,234 | Systematic analysis of loss-of-function variants across MODY genes demonstrates gene-specific effects and expands the spectrum of INS variants causing MODY. | Diabetologia | 2026 | https://conductscience.org/library/papers/41772234 | PubMed |
| 5 | 34,174,481 | In celebration of a century with insulin - Update of insulin gene mutations in diabetes. | Mol Metab | 2021 | https://conductscience.org/library/papers/34174481 | PubMed |
| 6 | 37,812,285 | Identification of monogenic diabetes in an Australian cohort using the Exeter maturity-onset diabetes of the young (MODY) probability calculator and next-generation sequencing gene panel testing. | Acta Diabetol | 2024 | https://conductscience.org/library/papers/37812285 | PubMed |
| 7 | 35,058,633 | Abnormal exocrine-endocrine cell cross-talk promotes β-cell dysfunction and loss in MODY8. | Nat Metab | 2022 | https://conductscience.org/library/papers/35058633 | PubMed |
| 8 | 23,771,172 | Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. | Diabetologia | 2013 | https://conductscience.org/library/papers/23771172 | PubMed |
| 9 | 16,885,550 | Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16885550 | PubMed |
| 10 | 40,819,284 | Maturity onset diabetes of the young and beyond: the changing face of single-gene diabetes. | Eur J Endocrinol | 2025 | https://conductscience.org/library/papers/40819284 | PubMed |
1 to 10 of 37
See all 37 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCC8 | 6,833 | PubTator's text mining | https://conductscience.org/library/genes/6833 | NCBI Gene |
| CEL | 1,056 | PubTator's text mining | https://conductscience.org/library/genes/1056 | NCBI Gene |
| INS | 3,630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| KCNJ11 | 3,767 | PubTator's text mining | https://conductscience.org/library/genes/3767 | NCBI Gene |
| NEUROD1 | 4,760 | PubTator's text mining | https://conductscience.org/library/genes/4760 | NCBI Gene |
| PDX1 | 3,651 | PubTator's text mining | https://conductscience.org/library/genes/3651 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42470517
GET https://conductscience.org/api/papers/v1/42470517/references?page=2